The ABRACL Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, designed to disrupt expression of the actin-binding protein ABRACL. This product provides a loss-of-function model for investigating ABRACL-dependent cytoskeletal reorganization, cell migration, and invasive behavior. The polyclonal knockout format reflects a heterogeneous pool of gene-edited cells generated without single-cell cloning, allowing researchers to study gene disruption effects in a context more closely resembling natural tumor cell heterogeneity.
The parental SK-HEP-1 cell line was originally isolated from the ascitic fluid of a patient with liver adenocarcinoma. This liver adenocarcinoma model is widely employed in hepatocellular carcinoma (HCC) and metastasis research due to its retained malignant properties. SK-HEP-1 cells exhibit epithelial morphology and have been extensively characterized for their tumorigenic potential and migratory capacity, making them an appropriate host for ABRACL functional studies in liver cancer.
ABRACL (ABRA C-terminal-like) is a key actin-binding protein that promotes actin polymerization and stress fiber formation by directly binding to F-actin and modulating the activity of actin regulators such as cofilin and profilin. FOXM1, a proliferation-associated transcription factor, transcriptionally upregulates ABRACL expression. ABRACL functions downstream of FOXM1 to enhance Rho GTPase signaling, including Rac1 and Cdc42, and contributes to focal adhesion dynamics. Additionally, ABRACL interacts with the Arp2/3 complex to facilitate branched actin networks, further driving lamellipodia formation and cell motility.
In the context of SK-HEP-1 liver adenocarcinoma cells, ABRACL knockout disrupts the FOXM1?CABRACL?CRho GTPase axis, leading to impaired actin cytoskeletal remodeling and reduced migratory and invasive capacity. This model is particularly relevant for dissecting the molecular mechanisms underlying hepatocellular carcinoma and colorectal cancer metastasis, where ABRACL overexpression has been associated with poor prognosis. By eliminating ABRACL function, researchers can evaluate the dependency of liver cancer cell migration on this actin-regulatory hub and assess therapeutic targets upstream or downstream.
Practical applications include cancer metastasis studies, cytoskeletal dynamics imaging, and anti-migratory drug testing. Representative assays that can be performed with these polyclonal knockout cells include wound healing scratch assays, Transwell migration and invasion chambers, phalloidin staining for F-actin visualization, quantitative RT-PCR, western blotting for pathway markers, and co-immunoprecipitation analyses of actin-binding complexes. For detailed technical specifications or to obtain this product, please contact Ascent Research.
